rewirebio.iobenchmarks
Source

Discovery of clinically relevant fusions in pediatric cancer

Europe PMC fullTextXML retrieved 2026-10-07T12:25:20.810843+00:00 · Peer-reviewed

DOI: 10.1186/s12864-021-08094-z

What this source contributed

Records in this release that cite this source. A record can cite several sources.

Results

Values as the source printed them. Compare results only under compatible protocols, datasets and metrics.

Model or configurationMetricValueDatasetEvaluation
ArribaCount (all fusion calls, mean of duplicates)23.5 countUndiluted Seraseq Fusion RNA control, duplicate librariesArriba evaluation
ArribaPrecision55.3% percentUndiluted Seraseq Fusion RNA control, duplicate librariesArriba evaluation
ArribaRecall92.9% percentUndiluted Seraseq Fusion RNA control, duplicate librariesArriba evaluation
ArribaTrue positives (seraseq spike-in fusions, mean of duplicates)13 countUndiluted Seraseq Fusion RNA control, duplicate librariesArriba evaluation
ArribaRecall (clinically relevant fusions)88.1% percentNationwide Children hospital pediatric cancer/hematologic cohortArriba NCH clinical-ascertainment evaluation
ArribaTrue positives (clinically relevant fusions)59 countNationwide Children hospital pediatric cancer/hematologic cohortArriba NCH clinical-ascertainment evaluation
EnFusion 3 callers + filter + known fusion listCount (all fusion calls, mean of duplicates)14 countUndiluted Seraseq Fusion RNA control, duplicate librariesEnFusion 3 callers + filter + known fusion list evaluation
EnFusion 3 callers + filter + known fusion listPrecision100.0% percentUndiluted Seraseq Fusion RNA control, duplicate librariesEnFusion 3 callers + filter + known fusion list evaluation
EnFusion 3 callers + filter + known fusion listRecall100.0% percentUndiluted Seraseq Fusion RNA control, duplicate librariesEnFusion 3 callers + filter + known fusion list evaluation
EnFusion 3 callers + filter + known fusion listTrue positives (seraseq spike-in fusions, mean of duplicates)14 countUndiluted Seraseq Fusion RNA control, duplicate librariesEnFusion 3 callers + filter + known fusion list evaluation
EnFusion 3 callersCount (all fusion calls, mean of duplicates)15.5 countUndiluted Seraseq Fusion RNA control, duplicate librariesEnFusion 3 callers evaluation
EnFusion 3 callersPrecision90.3% percentUndiluted Seraseq Fusion RNA control, duplicate librariesEnFusion 3 callers evaluation
EnFusion 3 callersRecall100.0% percentUndiluted Seraseq Fusion RNA control, duplicate librariesEnFusion 3 callers evaluation
EnFusion 3 callersTrue positives (seraseq spike-in fusions, mean of duplicates)14 countUndiluted Seraseq Fusion RNA control, duplicate librariesEnFusion 3 callers evaluation
STAR-FusionCount (all fusion calls, mean of duplicates)32 countUndiluted Seraseq Fusion RNA control, duplicate librariesSTAR-Fusion evaluation
STAR-FusionPrecision43.6% percentUndiluted Seraseq Fusion RNA control, duplicate librariesSTAR-Fusion evaluation
STAR-FusionRecall100.0% percentUndiluted Seraseq Fusion RNA control, duplicate librariesSTAR-Fusion evaluation
STAR-FusionTrue positives (seraseq spike-in fusions, mean of duplicates)14 countUndiluted Seraseq Fusion RNA control, duplicate librariesSTAR-Fusion evaluation
STAR-FusionRecall (clinically relevant fusions)94.0% percentNationwide Children hospital pediatric cancer/hematologic cohortSTAR-Fusion NCH clinical-ascertainment evaluation
STAR-FusionTrue positives (clinically relevant fusions)63 countNationwide Children hospital pediatric cancer/hematologic cohortSTAR-Fusion NCH clinical-ascertainment evaluation

Claims

Statements this source supports, each with where in the source it was checked.

  • Evidence summary: tumour RNA fusion detection workflows: Summary Four comparisons join the Seraseq reference and paediatric NCH cohort evidence; values cannot be pooled across studies. Tamura et al. 2026 ran 12 short-read callers on haematologic cancer cell lines; one, Genomon, comes from a co-author's group. On 61 driver fusions in conventional RNA-seq of 170 cell lines, Arriba detected all 61 (TPR 1), FusionCatcher 0.98, STAR-Fusion 0.93, InFusion 0.43 and STARChip 0.41. On 24 driver fusions in targeted RNA-seq of 26 cell lines, Arriba again reached 1 and STAR-Fusion 0.92, InFusion 0.17 and STARChip 0. A driver fusion entered these truth sets only if at least four callers, including the one scored, found it and it had literature or RT-PCR support, so fusions that most callers miss are under-represented and these values may overstate sensitivity. Against a consensus of the other callers, the number of single-caller calls, a measure of review burden, ranged on conventional RNA-seq from 327 for TrinityFusion-D and 1,061 for STAR-Fusion (PPV 0.39) to 9,567 for Arriba (PPV 0.08), 22,445 for FusionCatcher and 695,295 for Pizzly. On nanopore long reads from 51 paediatric B-ALL samples (Lin et al. 2026), scored on the dominant fusion per sample, JAFFAL reached sensitivity 0.76, LongGF 0.70 and FusionSeeker 0.63, with precision 0.79 to 0.95; the authors' own FUSILLI reached 0.81. At about one eighth of the depth, sensitivity was 0.09 to 0.27. In an independent long-read benchmark (Dorney et al. 2026 preprint), no caller exceeded F1 0.35 on 400 simulated fusions at 100 Gb and 95% read identity: CTAT-LR-Fusion 0.35 (recall 0.28, precision 0.46), JAFFAL 0.29, Genion 0.20, FusionSeeker 0.14, GFSeeker 0.07 and LongGF 0.04. On all ONT PCR-cDNA reads of the MCF7 cell line, CTAT-LR-Fusion's calls matched 20 of 53 previously reported fusions, with 51 other calls; JAFFAL matched 19 with 38 other calls and FusionSeeker 11 with 359. The other calls mix real fusions missing from the literature list and false calls. On the Huh7 cell line, pooling six long-read callers per long-read platform and three short-read callers for Illumina, PacBio Kinnex recovered 20 of 34 previously reported fusions, ONT PCR-cDNA 17 and Illumina 15. Against karyotyping, FISH and RT-PCR in 101 adult and paediatric acute leukaemia patients (Kim et al. 2026), an Arriba workflow with manual review detected 40 of 48 conventionally detected fusions (sensitivity 83.3%) and called fusions in 21.4% of 56 conventionally negative results; these count against specificity, although the authors describe several as well-known recurrent fusions and confirmed one by RT-PCR and Sanger sequencing. These are cell lines, simulations and leukaemia samples: no linked comparison covers solid-tumour specimens, FFPE tissue or novel-fusion discovery, only Kim et al. score against orthogonal clinical assays, none reports interval estimates, and none establishes clinical performance. (amp-oncology-rna-20261007-source-pmc8642973: Seraseq and NCH results; rna-fusion-20261009-source-tamura2026-supplementary: Supplementary Tables 3 and 5; rna-fusion-20261009-source-tamura2026: Methods and Author contributions; rna-fusion-20261009-source-lin2026: Tables 3 and 6, Results; rna-fusion-longread-20261011-source-dorney2026: see claims.csv of its batch; rna-fusion-longread-20261011-source-dorney2026-repository: see claims.csv of its batch; rna-fusion-leukaemia-20261011-source-kim2025: see claims.csv of its batch)
  • Relevance of EnFusion undiluted Seraseq duplicate benchmark to "Select a tumour RNA fusion-detection workflow": Assessed by EnFusion undiluted Seraseq duplicate benchmark (amp-oncology-rna-20261007-source-pmc8642973: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/)
  • Relevance of NCH clinically relevant fusion ascertainment to "Select a tumour RNA fusion-detection workflow": Assessed by NCH clinically relevant fusion ascertainment (amp-oncology-rna-20261007-source-pmc8642973: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/)

Models, benchmarks and other records

Configurations (6)

Protocols (2)

Datasets (2)

Evaluations (6)

Use cases (1)

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

21 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-11-21-adc15377fab2
Property and statementOriginal source and locationReview and provenance
Archive sha256
cf424d69172114c46db954db4f4f2caf6a638307ba8c1e71334e47463f16ca23
Source metadata
Discovery of clinically relevant fusions in pediatric cancer

Original source ↗

No field-specific location recorded

Version: Europe PMC fullTextXML retrieved 2026-10-07T12:25:20.810843+00:00
Retrieved: 2026-10-07T12:25:20.810843+00:00

catalogued

No individual claim review recorded

Audit details

Field: attributes.archive_sha256

Source artifact SHA-256: a5fd574d3b186fa29f835aff44491e1d1d0447ea2352f627c21f95ca666e9225

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Artifact SHA-256
a5fd574d3b186fa29f835aff44491e1d1d0447ea2352f627c21f95ca666e9225
Source metadata
Discovery of clinically relevant fusions in pediatric cancer

Original source ↗

No field-specific location recorded

Version: Europe PMC fullTextXML retrieved 2026-10-07T12:25:20.810843+00:00
Retrieved: 2026-10-07T12:25:20.810843+00:00

catalogued

No individual claim review recorded

Audit details

Field: attributes.artifact_sha256

Source artifact SHA-256: a5fd574d3b186fa29f835aff44491e1d1d0447ea2352f627c21f95ca666e9225

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Artifact url
https://www.ebi.ac.uk/europepmc/webservices/rest/PMC8642973/fullTextXML
Source metadata
Discovery of clinically relevant fusions in pediatric cancer

Original source ↗

No field-specific location recorded

Version: Europe PMC fullTextXML retrieved 2026-10-07T12:25:20.810843+00:00
Retrieved: 2026-10-07T12:25:20.810843+00:00

catalogued

No individual claim review recorded

Audit details

Field: attributes.artifact_url

Source artifact SHA-256: a5fd574d3b186fa29f835aff44491e1d1d0447ea2352f627c21f95ca666e9225

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Doi
10.1186/s12864-021-08094-z
Source metadata
Discovery of clinically relevant fusions in pediatric cancer

Original source ↗

No field-specific location recorded

Version: Europe PMC fullTextXML retrieved 2026-10-07T12:25:20.810843+00:00
Retrieved: 2026-10-07T12:25:20.810843+00:00

catalogued

No individual claim review recorded

Audit details

Field: attributes.doi

Source artifact SHA-256: a5fd574d3b186fa29f835aff44491e1d1d0447ea2352f627c21f95ca666e9225

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Licence
https://creativecommons.org/licenses/by/4.0/
Source metadata
Discovery of clinically relevant fusions in pediatric cancer

Original source ↗

No field-specific location recorded

Version: Europe PMC fullTextXML retrieved 2026-10-07T12:25:20.810843+00:00
Retrieved: 2026-10-07T12:25:20.810843+00:00

catalogued

No individual claim review recorded

Audit details

Field: attributes.licence

Source artifact SHA-256: a5fd574d3b186fa29f835aff44491e1d1d0447ea2352f627c21f95ca666e9225

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Media type
application/xml
Source metadata
Discovery of clinically relevant fusions in pediatric cancer

Original source ↗

No field-specific location recorded

Version: Europe PMC fullTextXML retrieved 2026-10-07T12:25:20.810843+00:00
Retrieved: 2026-10-07T12:25:20.810843+00:00

catalogued

No individual claim review recorded

Audit details

Field: attributes.media_type

Source artifact SHA-256: a5fd574d3b186fa29f835aff44491e1d1d0447ea2352f627c21f95ca666e9225

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Original artifact sha256
a5fd574d3b186fa29f835aff44491e1d1d0447ea2352f627c21f95ca666e9225
Source metadata
Discovery of clinically relevant fusions in pediatric cancer

Original source ↗

No field-specific location recorded

Version: Europe PMC fullTextXML retrieved 2026-10-07T12:25:20.810843+00:00
Retrieved: 2026-10-07T12:25:20.810843+00:00

catalogued

No individual claim review recorded

Audit details

Field: attributes.original_artifact_sha256

Source artifact SHA-256: a5fd574d3b186fa29f835aff44491e1d1d0447ea2352f627c21f95ca666e9225

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Publication status
peer_reviewed
Source metadata
Discovery of clinically relevant fusions in pediatric cancer

Original source ↗

No field-specific location recorded

Version: Europe PMC fullTextXML retrieved 2026-10-07T12:25:20.810843+00:00
Retrieved: 2026-10-07T12:25:20.810843+00:00

catalogued

No individual claim review recorded

Audit details

Field: attributes.publication_status

Source artifact SHA-256: a5fd574d3b186fa29f835aff44491e1d1d0447ea2352f627c21f95ca666e9225

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Retrieved at
2026-10-07T12:25:20.810843+00:00
Source metadata
Discovery of clinically relevant fusions in pediatric cancer

Original source ↗

No field-specific location recorded

Version: Europe PMC fullTextXML retrieved 2026-10-07T12:25:20.810843+00:00
Retrieved: 2026-10-07T12:25:20.810843+00:00

catalogued

No individual claim review recorded

Audit details

Field: attributes.retrieved_at

Source artifact SHA-256: a5fd574d3b186fa29f835aff44491e1d1d0447ea2352f627c21f95ca666e9225

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Review artifact format
original_source_artifact
Source metadata
Discovery of clinically relevant fusions in pediatric cancer

Original source ↗

No field-specific location recorded

Version: Europe PMC fullTextXML retrieved 2026-10-07T12:25:20.810843+00:00
Retrieved: 2026-10-07T12:25:20.810843+00:00

catalogued

No individual claim review recorded

Audit details

Field: attributes.review_artifact_format

Source artifact SHA-256: a5fd574d3b186fa29f835aff44491e1d1d0447ea2352f627c21f95ca666e9225

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

How to read the evidence

Sources and history

Release 2026-11-21-adc15377fab2 · Record review: source checked

Primary source for the AMP oncology-RNA bounded intake. Automated review, not independent reproduction.

Release history

No supporting source is linked yet.

Read original source

Download this release (gzip)
Technical metadata and extraction receipts

Stable ID: amp-oncology-rna-20261007-source-pmc8642973

archive sha256
cf424d69172114c46db954db4f4f2caf6a638307ba8c1e71334e47463f16ca23
artifact sha256
a5fd574d3b186fa29f835aff44491e1d1d0447ea2352f627c21f95ca666e9225
artifact url
https://www.ebi.ac.uk/europepmc/webservices/rest/PMC8642973/fullTextXML
doi
10.1186/s12864-021-08094-z
licence
https://creativecommons.org/licenses/by/4.0/
media type
application/xml
original artifact sha256
a5fd574d3b186fa29f835aff44491e1d1d0447ea2352f627c21f95ca666e9225
publication status
peer_reviewed
retrieved at
2026-10-07T12:25:20.810843+00:00
review artifact
data/omics/amp-coverage-20261007/oncology-rna/artifacts/PMC8642973.xml.gz
review artifact format
original_source_artifact
review artifact matches original artifact sha256
true
url
https://doi.org/10.1186/s12864-021-08094-z
version
Europe PMC fullTextXML retrieved 2026-10-07T12:25:20.810843+00:00
Related records

    Suggest a correction